S&P Futures
4,380.75 +8.75 (+0.20%) Dow Futures
34,363.00 +26.00 (+0.08%) Nasdaq Futures
14,920.25 +57.50 (+0.39%) Russell 2000 Futures
1,801.60 +3.70 (+0.21%) Crude Oil
90.50 +0.87 (+0.97%) Gold
1,945.90 +6.30 (+0.32%)
Athira Pharma, Inc. (ATHA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.0500 |
| Open | 2.0500 |
| Bid | 1.9800 x 1000 |
| Ask | 2.1500 x 1200 |
| Day's Range | 1.9800 - 2.0500 |
| 52 Week Range | 1.9400 - 4.4100 |
| Volume | |
| Avg. Volume | 223,679 |
| Market Cap | 76.109M |
| Beta (5Y Monthly) | 2.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7700 |
| Earnings Date | Nov 08, 2023 - Nov 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.33 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ATHA
Related Research
- Athira Pharma, Inc.Daily – Vickers Top Buyers & Sellers for 06/07/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat4 months agoArgus Research
GlobeNewswireAthira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in New York City. Details are as follows: 2023 Cantor Fitzgerald Global Healthcare Conferenc
ZacksAll You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ZacksDown -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)
Athira Pharma, Inc. (ATHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
